Literature DB >> 8368766

Adjuvant activity of QS-21 isomers.

S Soltysik1, D A Bedore, C R Kensil.   

Abstract

QS-21, a reverse-phase purified triterpene glycoside from the South American tree Quillaja saponaria, can be further resolved into two peaks when chromatographed by high performance hydrophilic interaction chromatography. These two peaks demonstrated identical pseudomolecular ion weights and fragmentation patterns when analyzed by fast atom bombardment-mass spectroscopy. Carbohydrate analysis by monosaccharide composition and linkage analysis showed that a terminal apiose in the major peak was replaced by another pentose residue in the minor peak. Hence, the two peaks were structural isomers. Dose response curves for each isomer and reverse-phase purified QS-21 were similar, with a minimum effective dose of 5 micrograms in mice. This result indicates that the portion of QS-21 containing this variation is not critical for adjuvant activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8368766     DOI: 10.1111/j.1749-6632.1993.tb44041.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

1.  Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.

Authors:  Govind Ragupathi; Payal Damani; Kai Deng; Michelle M Adams; Jianfeng Hang; Constantine George; Philip O Livingston; David Y Gin
Journal:  Vaccine       Date:  2010-05-05       Impact factor: 3.641

2.  Rapid assembly of the doubly-branched pentasaccharide domain of the immunoadjuvant jujuboside A via convergent B(C6F5)3-catalyzed glycosylation of sterically-hindered precursors.

Authors:  Rashad R Karimov; Derek S Tan; David Y Gin
Journal:  Chem Commun (Camb)       Date:  2017-05-30       Impact factor: 6.222

3.  Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Matthew B Laurens; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Mady Sissoko; Dapa A Diallo; Issa Diarra; Bourema Kouriba; Modibo Daou; Amagana Dolo; Mounirou Baby; Mahamadou S Sissoko; Issaka Sagara; Amadou Niangaly; Idrissa Traore; Ally Olotu; Olivier Godeaux; Amanda Leach; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; Darby Thompson; Tina Dube; Lorraine Soisson; Carter L Diggs; Shannon L Takala; Kirsten E Lyke; Brent House; David E Lanar; Sheetij Dutta; D Gray Heppner; Christopher V Plowe
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

4.  Versatile strategy for the divergent synthesis of linear oligosaccharide domain variants of Quillaja saponin vaccine adjuvants.

Authors:  Alberto Fernández-Tejada; Derek S Tan; David Y Gin
Journal:  Chem Commun (Camb)       Date:  2015-09-21       Impact factor: 6.222

5.  Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.

Authors:  Alberto Fernández-Tejada; Eric K Chea; Constantine George; Jeffrey R Gardner; Philip O Livingston; Govind Ragupathi; Derek S Tan; David Y Gin
Journal:  Bioorg Med Chem       Date:  2014-09-17       Impact factor: 3.641

6.  Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Dapa A Diallo; Issaka Sagara; Alassane Dicko; David J Diemert; D Gray Heppner; V Ann Stewart; Evelina Angov; Lorraine Soisson; Amanda Leach; Kathryn Tucker; Kirsten E Lyke; Christopher V Plowe
Journal:  PLoS Clin Trials       Date:  2006-11-24

7.  Development of a minimal saponin vaccine adjuvant based on QS-21.

Authors:  Alberto Fernández-Tejada; Eric K Chea; Constantine George; NagaVaraKishore Pillarsetty; Jeffrey R Gardner; Philip O Livingston; Govind Ragupathi; Jason S Lewis; Derek S Tan; David Y Gin
Journal:  Nat Chem       Date:  2014-06-01       Impact factor: 24.427

8.  Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Dapa A Diallo; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Alassane Dicko; Issaka Sagara; Mahamadou S Sissoko; Mounirou Baby; Mady Sissoko; Issa Diarra; Amadou Niangaly; Amagana Dolo; Modibo Daou; Sory I Diawara; D Gray Heppner; V Ann Stewart; Evelina Angov; Elke S Bergmann-Leitner; David E Lanar; Sheetij Dutta; Lorraine Soisson; Carter L Diggs; Amanda Leach; Alex Owusu; Marie-Claude Dubois; Joe Cohen; Jason N Nixon; Aric Gregson; Shannon L Takala; Kirsten E Lyke; Christopher V Plowe
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

9.  Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.

Authors:  Alberto Fernández-Tejada; Derek S Tan; David Y Gin
Journal:  Acc Chem Res       Date:  2016-08-28       Impact factor: 22.384

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.